Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Burroughs Wellcome Zovirax

This article was originally published in The Tan Sheet

Executive Summary

Article in May issue of Archives of Dermatology reports on long-term trial in over 400 patients with recurring genital herpes treated with oral acylovir 400 mg b.i.d. for more than five years. More than 20% of the patients receiving suppressive therapy have been recurrence free during the entire study, Leonard Goldberg, MD, Baylor College of Medicine, et al., reported. In addition, the study found that the "majority of patients were recurrence free on an annual basis during suppressive therapy" and and that therapy "was well-tolerated" and "not associated with serious side effects or cumulative toxicity." Burroughs Wellcome expects to file a supplemental NDA for an Rx-to-OTC switch of oral Zovirax for the prevention of genital herpes outbreaks this summer ("The Tan Sheet" May 10, In Brief).
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS081459

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel